Atlanta
– The Georgia
Department of Public Health(DPH) today is distributing an initial
allotment of the drug remdesivir received from the federal government. Georgia
received 30 cases, with 40 vials of the drug per case, enough to treat about
110 patients, depending on the duration of an individual’s treatment.
Remdesivir is an antiviral
medicine being used to treat hospitalized patients with serious symptoms caused
by COVID-19 like low oxygen levels or pneumonia. It has been found to shorten
the duration of disease in patients being treated in inpatient hospital
settings. Remdesivir is given intravenously (IV) and decreases the amount of
coronavirus in the body, helping patients recover faster.
The distribution plan for
remdesivir in Georgia was developed by DPH leadership, including district
health directors and emergency preparedness staff, in accordance with Food and
Drug Administration (FDA) guidelines for its use. It is based on the number of
patients on ventilators, the most severely ill, and clinical best practices.
Georgia hospitals receiving
remdesivir reported 10 or more COVID-19 positive patients on ventilators, in
addition to patients currently being treated with extracorporeal membrane
oxygenation (ECMO), a machine that takes over the work of the heart and lungs.
These criteria are subject to change based on the availability of remdesivir
and the development of patient care at hospital facilities across the state.
The following hospitals are
receiving remdesivir; Tift Regional Medical Center, Northeast Georgia Medical
Center, Wellstar Kennestone Hospital, Phoebe Putney Memorial Hospital, Grady
Health System, Emory University Hospital, Emory University Hospital Midtown,
and Augusta University Medical Center.
“DPH is pleased to have the
opportunity to share this promising treatment with hospitals on the front lines
in the fight against COVID-19,” said Kathleen E. Toomey, M.D., M.P.H., DPH
commissioner. “While this drug is not a cure for COVID-19, getting it into the
hospitals and improving patient outcomes is moving in the right direction.”
Georgia
has received a second, much larger allotment of remdesivir. DPH is surveying
hospitals statewide over the weekend to determine need. This second allotment
will be distributed next week.
Gilead
Sciences, Inc. committed to supplying approximately 607,000 vials of the
experimental drug over the next six weeks to treat an estimated 78,000
hospitalized COVID-19 patients under an emergency use agreement (EUA). The
donation to the United States is part of 1.5 million vials of remdesivir the
company is donating worldwide.
Remdesivir has not been approved by the FDA for widespread use because it is considered investigational and it is still being studied. Remdesivir was originally developed for use against Ebola. Clinical trials for remdesivir were done in Georgia at Emory University Hospital.
UPDATE 5.21.20
Second Allotment of Remdesivir Headed to Hospitals for Treatment of COVID-19
Atlanta
– The Georgia
Department of Public Health(DPH) is distributing a second allotment of
the drug remdesivir received from the federal government. Twenty-nine hospitals
in Georgia will receive remdesivir, enough to treat more than 300 patients,
depending on the duration of an individual’s illness and treatment needs.
Remdesivir is an antiviral
medicine being used to treat hospitalized patients with serious symptoms caused
by COVID-19 like low oxygen levels or pneumonia. It has been found to shorten
the duration of disease in patients being treated in inpatient hospital
settings. Remdesivir is given intravenously (IV) and decreases the amount of
coronavirus in the body, helping patients recover faster.
3,440 vials of remdesivir,
able to treat approximately 310 patients, will be distributed to 29 hospitals
affiliated with the following healthcare systems: Navicent, Northside, Piedmont
and WellStar.
Georgia hospitals receiving
remdesivir reported 10 or more COVID-19 positive patients on ventilators, in
addition to patients currently being treated with extracorporeal membrane
oxygenation (ECMO), a machine that takes over the work of the heart and lungs.
These criteria are subject to change based on the availability of remdesivir
and the development of patient care at hospital facilities across the state.
A third allotment of
remdesivir in powder form is expected to arrive in Georgia by Friday. The liquid
form of remdesivir is not recommended for pediatric use, but the powder form
can be mixed for dosing based on a child’s weight, which will provide treatment
for the youngest patients with COVID-19 infection.
Gilead
Sciences, Inc., the maker of remdesivir, is donating approximately 607,000
vials of the experimental drug to treat an estimated 78,000 hospitalized
COVID-19 patients under an emergency use agreement (EUA). The donation to the
United States is part of 1.5 million vials of remdesivir the company is
donating worldwide.
Remdesivir has not been
approved by the FDA for widespread use because it is considered investigational
and it is still being studied. Remdesivir was originally developed for use
against Ebola.
Clinical trials for remdesivir were done in Georgia at Emory University
Hospital.
For more
information about COVID-19 visit https://dph.georgia.gov/novelcoronavirus
or https://www.cdc.gov/coronavirus/2019-ncov/index.html.
For updates
on the COVID-19 situation as it develops, follow @GaDPH, @GeorgiaEMA, and
@GovKemp on Twitter, and @GaDPH, @GEMA.OHS, and @GovKemp on Facebook.